Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Witruth Capital

Investor type Private Equity Firm
Founders Frank Lu

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$27M
Portfolio companies 3
Lead investments 0
Key employees 2
Stages of investment
Private Equity

Areas of investment

  • Medical
  • Health Care
  • Biotechnology
  • Big Data
  • Manufacturing

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Witruth Capital:
Typical Co-investors
Witruth Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Witruth Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Avista Spokane, United States, Washington
China Chengxin Credit Beijing, Beijing, China
Deep Ventures California, San Francisco, United States
DHI Group, Inc. New York, New York, United States
DOCOMO InsightMarketing Japan, Toshima
Ever Sunny China, Hong Kong, Hong Kong Island
Gilead Sciences California, Foster City, United States
Hua Hsia Investment Holding Co Taipei, Taiwan
Interact for Health Cincinnati, Ohio, United States
JSR Corp Chiyoda, Japan
Kaiyuan Securities Capital Management China, Henan, Shanxi
LDGR Ventures -
Northrop Grumman Falls Church, United States, Virginia
Rosemont Investment Partners Conshohocken, Pennsylvania, United States
Rowad -
Shanda Interactive Entertainment Limited China, Shanghai
Weijia Investment China, Ningbo, Zhejiang
Whitman Capital California, Palo Alto, United States
Xenon Ventures Beaverton, Oregon, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Singlomics

Biotechnology
Health Care
Medical
$46M02 Feb 2022 Beijing, Beijing, China

Innovative Cellular Therapeutics

Biotechnology
Market Research
Therapeutics
$28M25 Apr 2018 Shanghai, China

Big Data
Health Care
Manufacturing
Medical
$7M08 Jul 2016 China, Zhejiang

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Witruth Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: